Vistin Pharma ASA ( (DE:VP4) ) has provided an announcement.
Vistin Pharma ASA reported its financial results for the fourth quarter and preliminary 2024, highlighting a revenue increase to MNOK 114 for the quarter due to improved sales volume. The company’s full-year revenue slightly declined to MNOK 430, but EBITDA reached an all-time high of MNOK 104, marking a 21% increase from the previous year. Strong operational performance and cost control contributed to this growth, despite challenges like an unplanned production stop. The Board plans to propose a dividend of NOK 1.25 per share, reflecting confidence in the company’s financial stability.
More about Vistin Pharma ASA
Vistin Pharma ASA operates in the pharmaceutical industry, focusing on the production of metformin, a medication primarily used for the treatment of type 2 diabetes. The company is known for its strong operational performance and market presence in the production of high-quality pharmaceutical products.
YTD Price Performance: 2.50%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €90.56M
Find detailed analytics on VP4 stock on TipRanks’ Stock Analysis page.